Overview

Novogaia develops medicines from fungi using AI and metabologenomics. It rapidly characterizes fungal chemical space and maps these molecules to biologically relevant and commercially viable targets in areas with unmet medical need. The core platform, Gaia-01, decodes natural samples into drug-like structures and links fungal chemistry discovery to target mapping for therapeutic development. Its go-to-market strategy provides product pages, demos, and documentation to help teams assess fit before rolling out Novogaia’s offering. The company’s approach combines fungal-derived drug discovery with AI-driven analysis to advance natural product medicines, aiming to de-risk targets and accelerate the development of fungal-derived drug programs through its metabologenomics platform and related tools.